-
Mashup Score: 0What Is the Role of Splenic Irradiation Before HSCT in Patients With MF? | Blood Cancers Today - 4 hour(s) ago
Splenic irradiation before HSCT is associated with reduced spleen size and lower incidence of relapse in patients with MF.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Geoff Chong, MD, Shares Data on Novel Bispecific Antibody in Follicular Lymphoma | Blood Cancers Today - 20 hour(s) ago
The ELM-2 trial studied odronextamab in patients with relapsed or refractory follicular lymphoma.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17Sanam Loghavi, MD: 'The HemOnc Pulse' Live Sheds a Spotlight on Hematopathology | Blood Cancers Today - 23 hour(s) ago
“I’m grateful to shed a spotlight on hematopathology and what we contribute to these patients,” Dr. Loghavi said.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 17Sanam Loghavi, MD: 'The HemOnc Pulse' Live Sheds a Spotlight on Hematopathology | Blood Cancers Today - 24 hour(s) ago
“I’m grateful to shed a spotlight on hematopathology and what we contribute to these patients,” Dr. Loghavi said.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 33
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Subcutaneous Sotatercept Is Safe, Effective in Patients With PMF, Anemia | Blood Cancers Today - 1 day(s) ago
Sotatercept monotherapy, and in combination with ruxolitinib, was found to be a safe and effective treatment for primary myelofibrosis.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Sotatercept alone, and combined with ruxolitinib, is a safe and effective treatment for patients with primary #myelofibrosis with anemia. Read more about the phase II trial, led by @bose_prithviraj, of @MDAndersonNews, and published in @Haematologica. 📰 https://t.co/HPfprxRT7D https://t.co/1f6kXGe7km
-
-
Mashup Score: 24Subscribe | Blood Cancers Today - 2 day(s) ago
Sign up for Blood Cancers Today eNewsletters to join an extensive community of hematologic oncology professionals and get the latest news and insights from the field.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 1Aditi Shastri, MD: Clinicians Needs to ‘Come Together’ on TP53-Mutated MDS | Blood Cancers Today - 2 day(s) ago
Using the VALIDATE database, researchers looked at treatment response to HMAs and overall survival in patients with TP53-mutated MDS.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2FDA Grants 510(k) Clearance to Sebia’s FLC Kappa, Lambda Assays for MM Diagnosis | Blood Cancers Today - 3 day(s) ago
Sebia’s free light chain (FLC) kappa and lambda assays have 510(k) clearance.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 9Low-Dose Azacitidine Plus Venetoclax Is Effective Maintenance for AML | Blood Cancers Today - 3 day(s) ago
Low-dose azacitidine plus venetoclax was a feasible maintenance regimen in AML after intensive or low-intensity induction therapy.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
Splenic irradiation before HSCT is associated with reduced spleen size and lower incidence of relapse in patients with #myelofibrosis. Read more about the study, led by @NicoGagelmann, of @UKEHamburg, and published in @AjHematology. 📰 https://t.co/miBqTylIH7 https://t.co/GEd0iiG0mf